All In Biotech

Drug Trial Radar · NCT04837508

A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

An Open-label, Single-arm, Multi-center, Phase II Clinical Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Last checked: Nov 19, 2026Latest source record: Dec 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

86

Planned (sponsor's estimate)

Start

Jun 7, 2021

Primary completion

Dec 2022

Study completion Aug 2023

Sponsor

Lead sponsor
Shanghai Miracogen Inc.Industry
Sponsor type
Industry
First posted
Apr 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 as single agent in HER2-positive unresectable locally advanced or metastatic biliary tract cancer patients who have progressed during or relapsed after at least one prior stand therapy.

Conditions

  • Advanced or Metastatic Biliary Tract Cancer

Interventions

  • MRG002Drug

    Administrated intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Baseline to study completion, up to 12 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • The first affiliated hospital of bengbu medical college

    Bengbu, Anhui, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • ZhuJiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Liaoning Cancer Hospital&Institute

    Shenyang, Liaoning, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.